IGFBP4: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of IGFBP4. The page also collects GeneMedi's different modalities and formats products for IGFBP4 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the IGFBP4 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. [provided by RefSeq, Jul 2008]
Target ID | GM-SE0986 |
Target Name | IGFBP4 |
Gene ID | 3487,16010,360622,700963,608158,101082792,282262,100034062 |
Gene Symbol and Synonyms | BP-4,Deb2,HT29-IGFBP,IBP-4,IBP4,IGF-BP4,IGFBP-4,IGFBP4 |
Uniprot Accession | P22692,P21744,Q05716 |
Uniprot Entry Name | IBP4_HUMAN,IBP4_RAT,IBP4_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Cytokine Target |
Disease | Pancreas Cancer, Dent disease |
Gene Ensembl | ENSG00000141753 |
Target Classification | N/A |
Pre-made anti-IGFBP4 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-IGFBP4 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-IGFBP4 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-IGFBP4 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Cytokine antibody | Detail |
Recombinant multi-species IBP4/ IGFBP4/ BP-4 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IGFBP4 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
IGFBP4 protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |
Cytokine Products for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces human, Cynomolgus/ Rhesus macaque, rat, mouse insulin-like growth factor binding protein 4 (IGFBP4) His+Avi (Biotinylated) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Insulin-like growth factor-binding protein 4 is a protein that in humans is encoded by the IGFBP4 gene. This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. IGFBP-4 is a unique protein and it consistently inhibits several cancer cells in vivo and in vitro. Its inhibitory action has been shown in vivo in prostate and colon. It is secreted by all colon cancer cells.
Target | Species | Antigen Product Name | Bioactivity validation of Antigen | Antibody Product Name | Bioactivity validation of Antibodies | Detail |
IGFBP4 | Human, Cynomolgus/Rhesus macaque, rat, mouse | insulin-like growth factor binding protein 4 (IGFBP4) protein | Affintiy&bioactivity validated by ELISA, cell culture validated | Anti-IGFBP4 monoclonal antibody | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). | Detail |
Click to check more Cytokine Products
Pre-made IGFBP4 viral vector in GM Promise-ORFTM
Cat No. | Products name | NM ID | Species | Type | Detail |
vGMLP003022 | human IGFBP4 Lentivirus particle | NM_001552 | Human | Lentivirus particle | Detail |
pGMLP003022 | human IGFBP4 Lentivirus plasmid | NM_001552 | Human | Lentivirus plasmid | Detail |
pGMLPm002827 | mouse Igfbp4 Lentivirus plasmid | NM_010517 | Mouse | Lentivirus plasmid | Detail |
vGMLPm002827 | mouse Igfbp4 Lentivirus particle | NM_010517 | Mouse | Lentivirus particle | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.